

Title (en)

ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND USES THEREOF

Title (de)

ANTI-INTEGRIN ALPHA BETA 3 ANTIKÖRPER-FORMULIERUNGEN UND IHRE VERWENDUNGEN

Title (fr)

PREPARATION D'ANTICORPS ANTI-INTEGRINE ALPHA BETA 3 ET UTILISATIONS ASSOCIEES

Publication

EP 1589996 A4 20090121 (EN)

Application

EP 04707034 A 20040130

Priority

- US 2004002701 W 20040130
- US 44377703 P 20030130
- US 44381003 P 20030130

Abstract (en)

[origin: WO2004066957A2] The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphanubeta3 , which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphanubeta3 , which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin alphanubeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

IPC 1-7

A61K 39/395; **C07K 16/28**

IPC 8 full level

A61K 39/395 (2006.01); **C07K 16/28** (2006.01)

IPC 8 main group level

A61K (2006.01)

CPC (source: EP)

A61K 39/39591 (2013.01); **A61P 1/04** (2017.12); **A61P 9/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12); **C07K 16/2848** (2013.01)

Citation (search report)

- [Y] WO 0213860 A1 20020221 - CHUGAI PHARMACEUTICAL CO LTD [JP], et al
- [Y] US 2001016645 A1 20010823 - HUSE WILLIAM D [US], et al & EP 1314437 A1 20030528 - CHUGAI PHARMACEUTICAL CO LTD [JP]
- See references of WO 2004066957A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004066957 A2 20040812; **WO 2004066957 A3 20050407**; AU 2004207003 A1 20040812; CA 2512174 A1 20040812; EP 1589996 A2 20051102; EP 1589996 A4 20090121; JP 2006516636 A 20060706

DOCDB simple family (application)

US 2004002701 W 20040130; AU 2004207003 A 20040130; CA 2512174 A 20040130; EP 04707034 A 20040130; JP 2006503199 A 20040130